Davis Richard, Reveles Kelly R, Ali Sayed K, Mortensen Eric M, Frei Christopher R, Mansi Ishak
Department of Medicine, Brooke Army Medical Center, Fort Sam Houston, TX, USA.
J Sex Med. 2015 Jan;12(1):158-67. doi: 10.1111/jsm.12745. Epub 2014 Nov 25.
Conflicting reports exist regarding the role of statins in male gonadal and sexual function. Some studies report a beneficial effect, particularly for erectile dysfunction (ED), through statins' anti-inflammatory and cardiovascular protective properties. Others suggest that statins might be associated with sexual dysfunction through negative effects on hormone levels.
This study aims to compare the risk of gonadal or sexual dysfunction in statin users vs. nonusers in a single-payer healthcare system.
This was a retrospective cohort study of all male patients (30-85 years) enrolled in the Tricare San Antonio market. Using 79 baseline characteristics, we created a propensity score-matched cohort of statin users and nonusers. The study duration was divided into a baseline period (October 1, 2003 to September 30, 2005) to describe patient baseline characteristics, and a follow-up period (October 1, 2005 to March 1, 2012) to determine patient outcomes. Statin users were defined as those prescribed a statin for ≥3 months between October 1, 2004 and September 30, 2005.
Outcomes were identified as the occurrence of benign prostatic hypertrophy (BPH), ED, infertility, testicular dysfunction, or psychosexual dysfunction during the follow-up period as identified by inpatient or outpatient International Classification of Diseases, 9th Revision, Clinical Modification codes. Logistic regression was used to determine the association of statin use with patient outcomes.
Of 20,731 patients who met study criteria, we propensity score-matched 3,302 statin users with 3,302 nonusers. Statin use in men was not significantly associated with an increased or decreased risk of BPH (odds ratio [OR] 1.08; 95% confidence interval [CI] 0.97-1.19), ED (OR 1.01; 95% CI 0.90-1.13), infertility (OR 1.22; 95% CI 0.66-2.29), testicular dysfunction (OR 0.91; 95% CI 0.73-1.14), or psychosexual dysfunction (OR 1.03; 95% CI 0.94-1.14).
Statin use was not associated with increased risk of being diagnosed with gonadal or sexual dysfunction in men. Further studies using a larger sample may be needed.
关于他汀类药物在男性性腺和性功能方面的作用,存在相互矛盾的报道。一些研究报告称,他汀类药物具有抗炎和心血管保护特性,对勃起功能障碍(ED)有有益作用。另一些研究则表明,他汀类药物可能通过对激素水平的负面影响而与性功能障碍有关。
本研究旨在比较单一支付者医疗系统中使用他汀类药物者与未使用者发生性腺或性功能障碍的风险。
这是一项对所有纳入特里卡尔圣安东尼奥市场的男性患者(30 - 85岁)进行的回顾性队列研究。我们利用79项基线特征,创建了一个倾向评分匹配的他汀类药物使用者和非使用者队列。研究持续时间分为基线期(2003年10月1日至2005年9月30日)以描述患者基线特征,以及随访期(2005年10月1日至2012年3月1日)以确定患者结局。他汀类药物使用者定义为在2004年10月1日至2005年9月30日期间服用他汀类药物≥3个月的患者。
结局被确定为在随访期间根据住院或门诊国际疾病分类第九版临床修订本代码确定的良性前列腺增生(BPH)、ED、不育、睾丸功能障碍或性心理功能障碍的发生情况。采用逻辑回归分析来确定他汀类药物使用与患者结局之间的关联。
在符合研究标准的20731名患者中,我们通过倾向评分匹配了3302名他汀类药物使用者和3302名非使用者。男性使用他汀类药物与BPH风险增加或降低无显著关联(优势比[OR] 1.08;95%置信区间[CI] 0.97 - 1.19),与ED(OR 1.01;95% CI 0.90 - 1.13)、不育(OR 1.22;95% CI 0.66 - 2.29)、睾丸功能障碍(OR 0.91;95% CI 0.73 - 1.14)或性心理功能障碍(OR 1.03;95% CI 0.94 - 1.14)也无显著关联。
男性使用他汀类药物与被诊断为性腺或性功能障碍的风险增加无关。可能需要进一步开展更大样本量的研究。